The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Denosumab: mechanism of action and clinical outcomes
Open accessAbstract
AIMS: To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. METHODS: Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. FINDINGS: Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high-risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. DISCUSSION: Effective pharmacotherapy is necessary for patients at high risk of fracture. Among the treatment options for postmenopausal osteoporosis, there are significant differences in mechanism and dosing. Denosumab acts by a novel mechanism and is administered twice yearly by subcutaneous injection. Identified by Osteoporosis Canada Clinical Practice Guidelines as a first-line agent for treatment of postmenopausal osteoporosis, denosumab represents an important addition to our treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Self-citation(2020) · Elsevier eBooks · doi:10.1016/c2015-1-01622-2 · Cited by 1,683
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Kanis, J. A., Borgstrom, F., De Laet, C., Johansson, H., Johnell, O., Jonsson, B., Oden, A., Zethraeus, N., Pfleger, B., & Khaltaev, N. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1780-5 · Cited by 1,233
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Cranney, A., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., Black, D., Adachi, J., Shea, B., Tugwell, P., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-2002 · Cited by 445
Self-citationPapapoulos, S., Chapurlat, R., Libanati, C., Brandi, M. L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Man, Z., Mellström, D., Radominski, S. C., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1479 · Cited by 344
(2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.x0001-8 · Cited by 332
Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 329
Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.81 · Cited by 286
Self-citationOsteoblasts in osteoporosis: Past, emerging, and future anabolic targets
Marie, P. J., & Kassem, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0132 · Cited by 234
Anabolic Therapy for Osteoporosis
Rosen, C. J. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.957 · Cited by 227
Seeman, E. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1340-9 · Cited by 220
Adachi, J. D., Adami, S., Gehlbach, S., Anderson, F. A., Boonen, S., Chapurlat, R. D., Compston, J. E., Cooper, C., Delmas, P., Díez-Pérez, A., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0082 · Cited by 199
Self-citationfor the CaMos Study Group, Papaioannou, A., Kennedy, C. C., Ioannidis, G., Sawka, A., Hopman, W. M., Pickard, L., Brown, J. P., Josse, R. G., Kaiser, S., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0743-7 · Cited by 191
Self-citationThe care gap in diagnosis and treatment of women with a fragility fracture
Bessette, L., Ste-Marie, L.-G., Jean, S., Davison, K. S., Beaulieu, M., Baranci, M., Bessant, J., & Brown, J. P. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0426-9 · Cited by 186
Kanis, J. А., Johansson, H., Odén, A., & McCloskey, E. V. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.04.061 · Cited by 170
Discoveries, drugs and skeletal disorders
Goltzman, D. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd916 · Cited by 168
Vitamin D and its implications for musculoskeletal health in women: An update
Pérez-López, F. R. (2007) · Maturitas · doi:10.1016/j.maturitas.2007.05.002 · Cited by 113
Canadian Consensus Conference on Osteoporosis, 2006 Update
Brown, J. P., Fortier, M. P., Frame, H., Lalonde, A. B., Papaioannou, A., Senikas, V., Yuen, C. K., Henneberg, E., Capistran, C., & Oman, J. (2006) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32087-4 · Cited by 94
Παπαϊωάννου, Α., Joseph, L., Ioannidis, G., Berger, C., Anastassiades, T., Brown, J. P., Hanley, D. A., Hopman, W. M., Josse, R. G., Kirkland, S., et al. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1735-x · Cited by 79
Self-citationClinical development of anti-RANKL therapies for treatment and prevention of bone metastasis
Lipton, A., & Goessl, C. D. (2010) · Bone · doi:10.1016/j.bone.2010.10.161 · Cited by 78
Denosumab: A Review of its Use in the Treatment of Postmenopausal Osteoporosis
Moen, M. D., & Keam, S. J. (2010) · Drugs & Aging · doi:10.2165/11203300-000000000-00000 · Cited by 75
Population-based Canadian hip fracture rates with international comparisons
For the Osteoporosis Surveillance Expert Working Group, Leslie, W. D., O’Donnell, S., Lagacé, C., Walsh, P., Bancej, C. M., Jean, S., Siminoski, K. G., Kaiser, S., Kendler, D. L., et al. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1080-1 · Cited by 73
Treatment of osteoporosis with denosumab
Lewiecki, E. M. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.02.008 · Cited by 62
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
Hiligsmann, M., Rabenda, V., Bruyère, O., & Reginster, J. (2010) · Health Policy · doi:10.1016/j.healthpol.2010.01.014 · Cited by 59
Rizzoli, R., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3244 · Cited by 51
Clinical update on teriparatide
File, E., & Deal, C. L. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0023-3 · Cited by 25
Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism
Yan, M., Xu, Y. J., Gong, Y., Liu, J., Lu, S., Huang, L. H., Wang, Z., Zhao, Y., & Pang, X.-F. (2009) · Endocrine · doi:10.1007/s12020-009-9267-y · Cited by 21
Pharmacological Mechanisms of Therapeutics
Hanley, D. A., Watson, P. H., Hodsman, A. B., & Dempster, D. W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00085-9 · Cited by 21
Self-citationData from Extension Trials: Denosumab and Zoledronic Acid
Dore, R. K. (2011) · Current Osteoporosis Reports · doi:10.1007/s11914-011-0082-z · Cited by 6
Cited by
Advances in the regulation of osteoclasts and osteoclast functions
Boyce, B. F. (2013) · Journal of Dental Research · doi:10.1177/0022034513500306 · Cited by 457
RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling
Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309
Hypercalcemia of malignancy: An update on pathogenesis and management
Mirrakhimov, A. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.170600 · Cited by 290
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Metadata
- Authors
- Hanley, D. A., Adachi, J. D., Bell, A., & Brown, V.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2012-09-12
- Volume
- 66
- Issue
- 12
- Pages
- 1139-1146
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- OpenAlex
- W1621696727
- Cited by
- 377
- References
- 51
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.